我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

冠心病介入治疗后阿托伐他汀致疲乏现象分析

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第2期
页码:
238-240
栏目:
临床研究
出版日期:
2010-12-10

文章信息/Info

Title:
Clinical analysis of atorvastatin-induced fatigue in patients following percutaneous coronary intervention
作者:
姜东炬; 孙飞; 贾玉琳; 胡高频; 付荣; 王冬冬
解放军210医院心内科，辽宁 大连 116021
Author(s):
JIANG Dong-ju;  SUN Fei;  JIA Yu-lin;  HU Gao-pin;  FU Rong;  WANG Dong-dong
Department of Cardiology, PLA 210 Hospital, Dalian 116012, Liaoning, China
关键词:
阿托伐他汀; 疲乏; 冠状动脉疾病
Keywords:
atorvastatin;  fatigue;  coronary disease
分类号:
R541.4；R972.6
DOI:
-
文献标识码:
A
摘要:
目的: 探讨阿托伐他汀在冠心病患者中疲乏发生率及对服药顺应性影响。方法： 入选介入治疗的冠心病患者477例（A组）和药物治疗患者312例（B组）。观察两组疲乏发生率、疲乏程度、对服药顺应性影响等，检测服药后肌酸激酶（CK）、丙氨酸氨基转移酶(ALT)及低密度脂蛋白胆固醇（LDL-C）水平。结果： ①两组患者的疲乏主要以轻度疲乏为主，A组的疲乏发生率明显高于B组，并且A组的疲乏发生率更多的发生在服药后0～3个月内；②调整阿托伐他汀类药物可以部分而不是全部缓解疲乏症状；③两组患者CK、ALT及LDL-C水平无明显差异，但重度疲乏患者CK浓度明显高于轻、中度疲乏患者。结论： 阿托伐他汀钙片引起的疲乏以轻度疲乏为主，在接受介入治疗的患者中疲乏的发生率偏高。
Abstract:
AIM: To investigate the incidence and degree of atorvastatin-induced fatigue in patients with coronary heart disease (CHD) and to study the impact of fatigue on medication compliance. METHODS: The incidence and degree of atorvastatin-induced fatigue and the impact of fatigue on medication compliance were investigated in 477 percutaneous coronary intervention (PCI)-treated CHD patients (group A) and 312 drug-treated CHD patients (group B). The effect of drug dosage adjustment on fatigue alleviation was studied and the levels of creatine kinase (CK), alanine aminotransferase (ALT) and low-density lipoprotein (LDL) after taking atorvastatin were measured. RESULTS: The incidence of atorvastatin-induced fatigue in group A was higher than in group B and fatigue mainly occurred within 0-3 months after medication in group A. Fatigue-related drug dosage adjustment was observed in both groups and the incidence of drug dosage adjustment due to mild fatigue was higher in group B. Dosage adjustment of atorvastatin alleviated the fatigue in some but not all patients. No significant difference was found in CK, ALT and LDL levels between groups, but CK level was higher in patients with severe fatigue than in patients with moderate or mild fatigue. CONCLUSION: Atorvastatin-induced fatigue is mainly mild and the incidence of fatigue was higher in patients with PCI.

参考文献/References

[1]Steinberg JG, Lesavre N, Paganelli F, et al. Effect of long-term atorvastatin treatment on the electrophysiological and mechanical functions of muscle［J］. Int J Clin Pharmacol Ther, 2006, 44(6): 251-261.

[2]Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke［J］. Arch Neurol, 2004, 61(6):889-892.

[3]Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients［J］. Atheroscler Thromb, 2005, 12(2):111-119.

[4]Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial［J］. Drug Saf, 2006, 29(8):703-712.

[5]Duncan AJ, Hargreaves IP, Damian MS, et al. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment［J］. Toxicol Mech Methods, 2009, 19(1):44-50.

[6]Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy［J］. Arch Neurol, 2005, 62(11):1709-1712.

[7]Johnson TE, Zhang X, Bleicher KB, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone［J］. Toxicol Appl Pharmacol, 2004, 200(3):237-250.

[8]Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy［J］. Am J Physiol Cell Physiol, 2006, 291(6):C1208-C1212.

[9]Pedersen SS, Daemen J, Van de Sande M, et al. Type-D personality exerts a stable, adverse effect on vital exhaustion in PCI patients treated with paclitaxel-eluting stents［J］. J Psychosom Res, 2007, 62(4):447-453.

[10]Kwaijtaal M, van Diest R, Br FW, et al. Inflammatory markers predict late cardiac events in patients who are exhausted after percutaneous coronary intervention［J］. Atherosclerosis, 2005, 182(2):341-348.

[11]Pedersen SS, Denollet J, Daemen J, et al. Fatigue, depressive symptoms, and hopelessness as predictors of adverse clinical events following percutaneous coronary intervention with paclitaxel-eluting stents［J］. J Psychosom Res, 2007, 62(4):455-461.

[12]Smith OR, Pedersen SS, Van Domburg RT, et al. Symptoms of fatigue and depression in ischemic heart disease are driven by personality characteristics rather than disease stage: a comparison of CAD and CHF patients［J］. Eur J Cardiovasc Prev Rehabil, 2008, 15(5):583-588.

备注/Memo

备注/Memo:
收稿日期：2010-05-19.通讯作者：姜东炬，主任医师，主要从事冠脉介入诊治研究Email:jiangdj1962@126.com
更新日期/Last Update: 2010-12-10